Full Generic Medicine Info
Dosage/Direction for Use

Cytomegaloviral retinitis in AIDS patients
Adult: Induction: 5 mg/kg by infusion over 1 hr once wkly for 2 consecutive wk. Maintenance: 5 mg/kg once every 2 wk, starting 2 wk after completion of induction treatment. Administer w/ oral probenecid 2 g, 3 hr prior to each cidofovir dose, further doses of 1 g at 2 and 8 hr after completion of infusion. Hydration: Infuse 1 L normal saline over 1-2 hr immediately before cidofovir infusion; if patient can tolerate additional water load, a 2nd liter may be given over 1-3 hr at the start of or immediately following infusion.
Renal impairment: Contraindicated.
Hypersensitivity to cidofovir and probenecid or other sulfur-containing medicines. Direct intraocular inj. Renal impairment (serum creatinine >1.5 mg/dL, CrCl ≤55 mL/min, or urine protein ≥100 mg/dL [≥2+ proteinuria]). Lactation. Concomitant use or w/in 7 days of treatment w/ potentially nephrotoxic drugs.
Special Precautions
Hepatic impairment. Pregnancy. Monitoring Parameters Monitor for renal function (serum creatinine and urine protein) w/in 48 hr prior each dose and WBC including neutrophil count prior to each dose; signs/symptoms of uveitis/iritis, metabolic acidosis.
Adverse Reactions
Nephrotoxicity, neutropenia, nausea, diarrhoea, headache, vomiting, fever, chills, asthenia, skin rash, dyspnoea, alopecia, ocular hypotony; iritis or uveitis. May cause hypospermia.
Potentially Fatal: Acute renal failure, metabolic acidosis w/ hepatic impairment and pancreatitis.
Drug Interactions
Increased risk of adverse inflammatory effects when administered w/ 2-4 wk of intravitreal fomivirsen.
Potentially Fatal: Increased risk of nephrotoxicity w/ potentially nephrotoxic drugs (e.g. aminoglycosides, amphotericin B, foscarnet, IV pentamidine, vancomyicn, NSAIDs).
Cidofovir is a purine nucleotide analog that is active against herpesviruses and certain other viruses. It is converted to its active intracellular metabolite, cidovir diphosphate, and supresses CMV replication by selectively inhibiting viral DNA synthesis. Also, it reduces the rate of viral DNA synthesis by incorporation into growing viral DNA chains.
Distribution: Volume of distribution: 0.41 L/kg. Plasma protein binding: <6%.
Metabolism: Minimally metabolised via intracellular phosphorylation by cellular kinases to cidofovir diphosphate.
Excretion: Via urine (70-85% as unchanged drug). Elimination half-life: Approx 2.6 hr.
Intravenous: Store below 25°C.
CIMS Class
ATC Classification
J05AB12 - cidofovir ; Belongs to the class of nucleosides and nucleotides excluding reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Disclaimer: This information is independently developed by CIMS based on cidofovir from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in